Do we have enough evidence overall, or should we wait for ongoing trials? Source: International Congress 2014 – From respiratory infections to wheezing: reevaluating the role of vitamin D levels in childhood Year: 2014
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
What have we learn from rebiospy studies? Source: ERS Research Seminar Year: 2015
Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014
How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014
Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Source: Eur Respir J 2014; 44: 1123-1126 Year: 2014
From the bedside: upcoming new clinical strategies Source: International Congress 2016 – Scientific Year in Review 2016 Year: 2016
Pirfenidone: an update on clinical trial data and insights from everyday practice Source: Eur Respir Rev 2014; 23: 111-117 Year: 2014
How to treat IPF: lessons from the NIH-IPF-Net treatment trials Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014
Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021
Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019
Large trials, new knowledge: the changing face of COPD management Source: Eur Respir J 2015; 45: 1692-1703 Year: 2015
Clinical trial landscape for M/XDR-TB: current evidence and future perspectives Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
Are we wasting money on premature and badly designed clinical trials? Source: International Congress 2015 – Acute lung injury research: are we doing the right things? Year: 2015
Randomised controlled trials and real-life studies: two answers for one question Source: Eur Respir Rev, 27 (149) 180080; 10.1183/16000617.0080-2018 Year: 2018
A new model for clinical trials to address the COVID-19 emergency Source: Breathe, 16 (2) 200220; 10.1183/20734735.0220-2020 Year: 2020
Was the implementation strategy of the ProACT trial adequately proactive? Source: Breathe, 15 (1) 77; 10.1183/20734735.0338-2018 Year: 2019